Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7545492 | 1.00 | USP30 (0.53) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL7545508 | 1.00 | USP30 (0.53) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL1055082 | 0.88 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL14037432 | 0.88 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL853539 | 0.88 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL13177349 | 0.88 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL853540 | 0.88 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL1718729 | 0.87 | S1PR5 (0.45) | USP30SIGMAR1S1PR5S1PR1 | |
| SCHEMBL1718731 | 0.87 | S1PR5 (0.45) | USP30SIGMAR1S1PR5S1PR1 | |
| SCHEMBL1891026 | 0.85 | USP30 (0.54) | USP30L3MBTL1ATMALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-10793579-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3536685-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | Pfizer Inc (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190270751-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10329302-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180127432-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9879022-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-6372764-B1 | ANTIINFLAMMATORY AGENTS AND AIDS TREATMENT | MERCK & CO., INC. | 2002-04-16 | — | — | US | disclosed |
| EP-0726269-B1 | QUINOLINECARBOXYLIC ACID DERIVATIVES AND SALTS THEREOF | KAKEN PHARMA CO LTD (JP) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000051609-A1 | 3-ALKYL SUBSTITUTED PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051610-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5668147-A | ANTIBIOTICS, BACTERICIDES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1997-09-16 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0726269-A1 | QUINOLINECARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1996-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270751-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | USP30 4453/4885L3MBTL1 4668/4885ATM 1496/4885 |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | USP30 4453/4885L3MBTL1 4668/4885ATM 1496/4885 |
| US-10793579-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | USP30 4453/4885L3MBTL1 4668/4885ATM 1496/4885 |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | TTR, TYR, ABL1 | USP30 3230/4885L3MBTL1 3017/4885ATM 949/4885 |
| US-10329302-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | USP30 4453/4885L3MBTL1 4668/4885ATM 1496/4885 |
| US-20180127432-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | USP30 4453/4885L3MBTL1 4668/4885ATM 1496/4885 |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | USP30 4453/4885L3MBTL1 4668/4885ATM 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.